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OBJECTIVE
• Discuss the key components of 
research/evidence-based practice (EBP)
– Prophylaxis for venous thromboembolism
• Arthroplasty
– Consensus Guidelines
– New Study Data
• Understand the research question
– Can a delayed ‘dose’ provide the same level of 
effectiveness and safety, as other ‘standard’ 
strategies?
• Facilitate research to assess results and 
implications for clinical practice at Lehigh Valley 
Hospital
Venous Thromboembolism (VTE)
 Deep venous thrombosis (DVT)
 Pulmonary embolism (PE)
– PE is the most frequent cause of death 
following total joint arthroplasty
 Post-thrombotic syndrome (PTS)
VIRCHOW’s
TRIAD
Clinical Risk Factors For VTE
• History of VTE




• Genetic predisposition to hematologic abnormalities
• Trauma
• Other: malignancy, coronary syndromes (e.g., unstable angina)
• Major surgery (e.g., total joint arthroplasty)




 PE and DVT account for 250,000 hospitalizations 
each year
 3rd most common cardiovascular disease
 PE is often clinically silent:
– 50% asymptomatic PE in symptomatic proximal DVT
– Up to 30% in calf DVT
J AM Col Cardiol 2000; 36:970-1062
Current Strategies for VTE 
Prophylaxis 
• Mechanical prophylaxis
• Pharmacologic anticoagulant therapy
Current Options for VTE prophylaxis
Recommended DVT/VTE Prophylaxis
Risk group Recommended prophylaxis
Hip replacement Warfarin, LMWH, fondaparinux
Knee replacement             Warfarin, LMWH, IPC, 
fondaparinux (Arixtra)
Hip fracture Warfarin, LMWH, fondaparinux
Major trauma LMWH, IPC
Abdominal surgery UFH, LMWH, IPC, warfarin, ES
Medical patients UFH, LMWH, ES
IPC-Intermittent Pneumatic Compression 
SCD - Sequential Compression Devices
ES-Elastic stocking
LMWH-Low Molecular Weight Heparin
Geerts et al Chest 2004
Mechanical Prophylaxis
• Intermittent pneumatic compression (IPC)
• Pneumatic plantar compression (foot pump)
• Advantages
– Local anti-stasis effects
– Systemic humoral effects









– Unfractionated heparin (UFH)
– Low-molecular-weight heparins (LMWHs)
• Novel anticoagulation therapies
– Thrombin inhibitors (lepirudin and others in 
development)
– Factor Xa inhibitors (fondaparinux)
































Targeted Mechanism of Action






 Specific inhibition of factor Xa via antithrombin
 Highly selective for its target
 100% bioavailability
 Efficacious and safe
 Total chemical synthesis: 
- Batch-to-batch consistency
- Single chemical entity
-Specific inhibition of factor Xa via antithrombin
-Highly selective for its target                             
-100% bioavailability                                            
-Effective and afe                                                
-Total chemical synthesis                                     
Pre-Study Evidence-Based 
Observations
– Numerous studies and the 7th ACCP Guidelines 
recommend various VTE (venous thromboembolism) 
prophylaxis regimens around arthroplasty procedures
• No definitive answers
– 5 recent published trials suggest fondaparinux is at 
least equally effective to enoxaparin for VTE 
prophylaxis after arthroplasty-dosed approximately 6 
hours after surgery
– The Pentamaks trial suggests possibly more bleeding
• Timing of dose may play a part in bleeding risk
2004 ACCP Guidelines-VTE Prophylaxis
Geerts, WH; Pineo, GF; Heit, JA et al.
[The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-based Guidelines] 
























Incidence of Major Bleeding* With ARIXTRA Therapy by 
Time of First Active Postoperative Dose in Perioperative 
Prophylaxis Clinical Studies. (N=3,265) 
Study Question
• “Would a ‘delayed’ dose of fondaparinux 
given 18-24 hours post procedure provide 
the same level of efficacy and safety, as 
the use of standard warfarin and 
enoxaparin regimens?”
WHY is VTE prophylaxis 
IMPORTANT in 
arthroplasty??
Implications for Clinical 
Practice
Orthopedic Procedures 
on the Rise 
Paiement GD, Mendelsohn C. The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data.
Orthopedics. 1997;20(suppl):7-9.
AAOS Web site. Available at: http://orthoinfo.aaos.org/booklet/bookview.cfm?Thread_ID=2&topcategory=Hip. Accessed June 12, 2001.
AAOS Web site. Available at: http://orthoinfo.aaos.org/booklet/bookviacfm?Thread_ID=2&topcategory=knee. Accessed June 12, 2001.
 An increase in the number of orthopedic 
procedures is due to:
– Increased life expectancy
– Growing population of older individuals
 Total knee replacement: 266,000/year in the US
 Total hip replacement: 168,000/year in the US
Risk for DVT/VTE
















Geerts et al; Chest 2001, 2004
The Importance of VTE 
Prophylaxis in Hip Arthroplasty
Adapted from Paiement GD and Mendelsohn C. The risk of venous thromboembolism in the orthopedic patient: epidemiological and 














* Diagnosed by routine enography and ±10%
** Diagnosed by routine enography and ±5%











Fatal PE Proximal DVT All DVT
Design of Study
• Retrospective review
• Comparison of ‘consecutive’ non-emergent 
arthroplasty cases
– Potential flaws
• cannot perfectly match for co-morbidities
• similar surgical expertise assumed
• similar post-surgical care assumed
• only single center evaluation
• patient follow-up at other centers could not be 
accounted for
¤ Consecutive records of all elective major orthopedic 
procedures related to total knee and hip replacements
-data from first 6 months of 2004 
¤ Comparative groups
-n=185; received fondaparinux 
-n=550; received other ‘standard’ VTE
prophylaxis regimens
¤ Electronic chart review by Pharmacists to collect pre-
selected outcomes 
¤ Patient outcomes reviewed
- all cause 30 day readmissions, bleeding 
- all cause 30 day readmissions, VTE event
- any in- hospital mortality 
- in-hospital VTE events
Methods
Table 1: Patient Demographics Study Group    Standard Group
(n=185)  <%> (n=550)  <%>
Male 67        <36.2> 211      <38.4>
Female 118      <63.8> 339      <61.6>
LOS median (days) 3.0 3.1
LOS mean (days) 3.55 3.67
Age mean (years) 65.1 64.7
Hip replacement 76       <41.1> 221     <40.2>
Knee replacement 109    <58.9> 329     <59.8>
RESULTS—Similar demographics





































*Fisher’s Exact test:  There is no difference 
between the groups for p value> 0.05
Conclusions
• Patients at Lehigh Valley Hospital were 
provided with similar levels of safe and 
effective VTE prophylaxis after non-
emergent arthroplasty procedures 
regardless of the strategy utilized to 
augment post operative care.
• These results have been confirmed by a 
multi-center study---FLEXTRA.
